Drug Trial Radar · NCT06470828
A Study of TAK-861 for the Treatment of Narcolepsy Type 1
Last checked: Nov 20, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
168
Actual
Start
Jul 2, 2024
Primary completion
Jun 3, 2025
Study completion Jun 3, 2025
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Jun 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main aim of this study is to learn how effective TAK-861 (oveporexton) is in improving excessive sleepiness during the day (called excessive daytime sleepiness or EDS) after 3 months of treatment. Other aims are to learn how effective TAK-861 (oveporexton) is in lowering the number of sudden, unexpected attacks of muscle weakness while staying conscious (cataplexy) in a week; to learn the effect TAK-861 (oveporexton) has on participants' ability to maintain attention, participant's overall quality of life, the spectrum of narcolepsy symptoms, and daily life functions; and to learn about the safety of TAK-861 (oveporexton).
Conditions
- Narcolepsy Type 1
Interventions
OveporextonDrug
Oral tablet.
PlaceboDrug
OVE-matching placebo tablet.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 12 in Mean Sleep Latency From the 4 Maintenance of Wakefulness Test (MWT) Wake TrialsTime frame: Baseline, Week 12
Locations
53 sites in 11 countries. Site status is shown where the registry gives one.
Takeda Site 48
Phoenix, Arizona
Takeda Site 39
Redwood City, California
Takeda Site 31
Santa Ana, California
Takeda Site 18
Upland, California
Takeda Site 4
Orlando, Florida
Takeda Site 3
Atlanta, Georgia
Takeda Site 45
Boston, Massachusetts
Takeda Site 5
St Louis, Missouri
Takeda Site 2
Denver, North Carolina
Takeda Site 6
Cincinnati, Ohio
Takeda Site 42
Cleveland, Ohio
Takeda Site 49
Danville, Pennsylvania
Takeda Site 1
Columbia, South Carolina
Takeda Site 44
Dallas, Texas
Takeda Site 10
Norfolk, Virginia
Takeda Site 21
Ottawa, Ontario, Canada
Takeda Site 11
Toronto, Ontario, Canada
Takeda Site 50
Montreal, Quebec, Canada
Takeda Site 40
Lyon, France
Takeda Site 29
Paris, France
Takeda Site 25
Montpellier, Herault, France
Takeda Site 43
Toulouse, Midi-Pyrenees, France
Takeda Site 34
Berlin, Germany
Takeda Site 26
Schwerin, Germany
Takeda Site 47
Regensberg, Bavaria, Germany
Takeda Site 30
Bologna, Italy
Takeda Site 32
Rome, Lazio, Italy
Takeda Site 16
Kurume-shi, Fukuka-Ken, Japan
Takeda Site 13
Kitakyushu-shi, Fukuoka, Japan
Takeda Site 14
Fukuoka, Fukuoka-Shi Hakata-Ku, Japan
Takeda Site 9
Kohoku, Kanagawa, Japan
Takeda Site 7
Kumamoto, Kumamoto, Japan
Takeda Site 17
Isahaya-shi, Nagasaki, Japan
Takeda Site 15
Urasoe-Shi, Okinawa, Japan
Takeda Site 12
Yodogawa, Osaka, Japan
Takeda Site 8
Bunkyo-ku, Tokyo, Japan
Takeda Site 19
Kodaira-shi, Tokyo, Japan
Takeda Site 20
Shibuya-ku, Tokyo, Japan
Takeda Site 28
Zwolle, Netherlands
Takeda Site 33
Oslo, Norway
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.